GSK plans to divest old drugs except in emerging markets
This article was originally published in Scrip
GlaxoSmithKline has plans to divest its older drugs in European and US regions, but it is in no rush to strike a deal and nor does it think any mega transactions will take place for its established products portfolio, a source familiar with the matter told Scrip.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.